References
- Tefferi A, Vardiman JW. Myelodysplastic syndromes. N. Engl. J. Med.361(19), 1872–1885 (2009).
- Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood89(6), 2079–2088 (1997).
- Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract. Res. Clin. Haematol.14(3), 479–495 (2001).
- Russell M, List A, Greenberg P et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood84(4), 1243–1248 (1994).
- Dreyfus F Bouscary D, Melle J, Ribrag V, Guesnu M, Varet B. Expression of the Evi-1 gene in myelodysplastic syndromes. Leukemia9(1), 203–205 (1995).
- Sole F, Espinet B, Sanz GF et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br. J. Haematol.108(2), 346–356 (2000).
- Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature251(5474), 437–438 (1974).
- Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q- anomaly. Cancer Genet. Cytogenet.17(3), 189–255 (1985).
- Boultwood J, Fidler C, Strickson AJ et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood99(12), 4638–4641 (2002).
- Gondek LP, Dunbar A, O’Keefe C et al. SNP-A based karyotyping facilitates improved mapping of deletions and uniparental disomy within the long arm of chromosome 5 in myeloid disorders. Blood110(11), (2007) (Abstract 2435).
- Boultwood J, Pellagatti A, Cattan H et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br. J. Haematol.139(4), 578–589 (2007).
- Ebert BL, Pretz J, Bosco J et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature451(7176), 335–339 (2008).
- Barlow JL, Drynan LF, Hewett DR et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat. Med.16(1), 59–66 (2010).
- McGowan KA, Li JZ, Park CY et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat. Genet.40(8), 963–970 (2008).
- Lamothe B, Besse A, Campos AD et al. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I k B kinase activation. J. Biol. Chem.282(6), 4102–4112 (2007).
- Starczynowski DT, Kuchenbauer F, Argiropoulos B et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med.16(1), 49–58 (2009).
- List A, Dewald G, Bennett J et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med.355(14), 1456–1465 (2006).
- Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer4(4), 314–322 (2004).